Foghorn Therapeutics Stock In The News

FHTX Stock  USD 6.50  0.31  5.01%   
Our overall analysis of Foghorn Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Foghorn Therapeutics. The specific impact of Foghorn Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Foghorn Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Foghorn Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Foghorn Therapeutics Backtesting and Foghorn Therapeutics Hype Analysis.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Foghorn Therapeutics Today Top News and Investor Outlook

Yahoo News
Flagship Pioneering, the National Univer...
https://finance.yahoo.com/news/flagship-pioneering-national-university-singapore-021200382.html
 Bullish
Macroaxis News: globenewswire.com
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
https://www.globenewswire.com/news-release/2025/05/01/3072208/0/en/Foghorn-Therapeutics-Appoints-Neil-Gallagher-and-Stuart-Duty-to-its-Board-of-Directors.html
 Neutral
Macroaxis News: globenewswire.com
Foghorn Therapeutics Presents New Precli...
https://www.globenewswire.com/news-release/2025/04/28/3069635/0/en/Foghorn-Therapeutics-Presents-New-Preclinical-Data-on-Selective-SMARCA2-Inhibitor-FHD-909-and-Selective-CBP-and-Selective-EP300-Degrader-Programs-and-Provides-Pipeline-Update.html
 Neutral
Macroaxis News: globenewswire.com
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
https://www.globenewswire.com/news-release/2025/04/15/3061552/0/en/Foghorn-Therapeutics-to-Host-Virtual-Investor-Event-to-Review-Pipeline-Updates-in-Conjunction-with-2025-AACR-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Foghorn Therapeutics Announces New Precl...
https://www.globenewswire.com/news-release/2025/03/25/3049200/0/en/Foghorn-Therapeutics-Announces-New-Preclinical-Data-for-Selective-SMARCA2-Inhibitor-FHD-909-and-Selective-CBP-and-EP300-Degrader-Programs-at-2025-AACR-Meeting.html
 Neutral
Yahoo News
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
https://finance.yahoo.com/news/charles-river-valo-health-identify-120000756.html
 Bullish
Macroaxis News: globenewswire.com
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
https://www.globenewswire.com/news-release/2025/03/06/3038601/0/en/Foghorn-Therapeutics-Provides-Financial-Update-for-2024-and-2025-Strategic-Outlook.html
 Neutral
Macroaxis News: globenewswire.com
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2025/02/25/3031828/0/en/Foghorn-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html
 Bullish
Yahoo News
Flagship Pioneering Announces Appointmen...
https://finance.yahoo.com/news/flagship-pioneering-announces-appointment-junaid-120000935.html
 Bullish
Yahoo News
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
https://finance.yahoo.com/news/invaio-sciences-appoints-andr-andonian-120000404.html
 Bullish

Foghorn Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Foghorn and other traded companies coverage with news coverage. We help investors stay connected with Foghorn headlines for the 29th of July to make an informed investment decision based on correlating the impacts of news items on Foghorn Stock performance. Please note that trading solely based on the Foghorn Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Foghorn Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Foghorn Therapeutics investors visualize upcoming and past events in order to time the market based on Foghorn Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Foghorn Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Foghorn Therapeutics' short interest history, or implied volatility extrapolated from Foghorn Therapeutics options trading.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.